Investigating a new treatment for a severe lung disease after stem cell transplants
Official title: Bronchiolitis Obliterans: Discovery and Therapy
Funded at Dana-Farber Cancer Inst · NIH-10914143 · Data updated 2026-11-12
This study is looking at a lung condition called Bronchiolitis Obliterans Syndrome (BOS) that can happen after certain types of stem cell transplants, and it's testing a new drug, KD025, to see if it can help improve lung health for patients dealing with this tough issue.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 15, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $636,798 |
| NIH project number | 5P01HL158505-03 |
| Project ID | NIH-10914143 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have developed Bronchiolitis Obliterans Syndrome following allogeneic hematopoietic cell transplantation.
✕Less likely to help
Patients who have not undergone hematopoietic cell transplantation or those without a diagnosis of Bronchiolitis Obliterans Syndrome are unlikely to benefit from this research.
What this research studies
This research focuses on Bronchiolitis Obliterans Syndrome (BOS), a serious lung condition that can develop after allogeneic hematopoietic cell transplantation. The study aims to understand the disease's underlying mechanisms and test a new drug, KD025, which may help reverse the lung damage caused by BOS. By utilizing advanced lung organoid cultures and immunogenomics, researchers will identify the specific immune targets involved in BOS and evaluate the effectiveness of the treatment in a clinical trial. Patients participating in this research may contribute to significant advancements in the management of this challenging condition.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that significantly improves lung function and survival rates for patients with BOS.
How similar studies have gone: Previous research has shown promise in treating related conditions with similar immunologic approaches, indicating potential for success in this novel treatment.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Cutler, Corey S — Dana-Farber Cancer Inst
- Study coordinator: Cutler, Corey S
Related research
Other NIH-funded projects on the same topics.
-
Airway basal cell stress and environmentally caused bronchiolitis obliterans
Researchers are studying how certain inhaled chemicals may damage the airway’s foundational cells and lead to a serious lung disease called bronchiolitis obliterans.
-
Bronchiolitis Obliterans: turning biology insights into potential therapy
A potential new therapy for a serious lung disease that can occur after stem cell transplant is being tested to see if it can reverse damage and improve breathing.
-
Interrupting harmful lung cell interactions to reduce fluid leakage in critically ill children with bronchiolitis
AYA pediatric patients with bronchiolitis who are severely ill may benefit from a study that targets lung cell signals to lessen fluid leak and improve breathing.
-
Airway stem cell problems in transplant-related obliterative bronchiolitis
This work looks at how airway stem cells change after lung transplant to help people who develop obliterative bronchiolitis.
-
Lymphatic changes after lung transplant and risk of bronchiolitis obliterans
Researchers are looking at how damage or repair of the lung's lymphatic vessels after transplant affects the chance of developing bronchiolitis obliterans in people who receive lung transplants.
-
How respiratory viruses affect long-term lung damage after donor stem cell transplant
Following people who had donor stem cell transplants to see how common respiratory viruses relate to long-term lung damage called bronchiolitis obliterans syndrome.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.